Study | Country | Number of patients | Inclusion criteria | Intervention | Age | Sex | Systolic blood pressure | Heart rate | MDA | TAC | CKMB | Mortality rate | Ventillation rate | Hospitalization time | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tehrani, H. et al. 2013 | Iran | 37(22 in intervention and 15 in control) | Acute aluminum phosphide-intoxicated patients with no history of diabetes mellitus, cardiovascular, respiratory, renal and hepatic failure, and no medical management for aluminum phosphide poisoning in any medical center before. admission | NAC (140 mg/Kg/IV infusion as a loading dose and 70 mg/Kg/IV infusion every 4 h up to 17 doses) | 23.5 ± 7.8 24.7 ± 6.4 | M/F29.7%/29.7% M/F21.6%/18.9% | 93.7 ± 17.8 87.3 ± 13.6 | 88.7 ± 17.1 94.6 ± 21.1 | On admission: 195.7 ± 67.4 139 ± 28.2 24 h after admission 174.6 ± 48.9 149.6 ± 35.2 | On admission 11.4 ± 2.2 13.3 ± 2.5 24 h after admission 12.8 ± 5.7 17.3 ± 5.6 | NA NA | Intervention group: 36% (8 out of 22) Control group: 60% (9 out of 15) | Intervention group: 45.4% (10 out of 22) Control group: 73.3% (11 out of 15) | 2.7 ± 1.8 days 8.5 ± 8.2 days | ||||||
Bhalla A. et al. 2017 | India | 50(24 in intervention and 26 in control) | All the patients presenting to emergency outpatient department with alleged history of ingestion of ALP was screened and those. with shock were eligible | NAC in the dose of 150 mg/kg intravenous over 1 h, followed by 50 mg/kg over 4 h, followed by 100 mg/kg 16 h in 5% dextrose | < 30 years:24% 40% > 30 years:24% 12% | M/F38%/10% M/F32%/20% | 77.52 ± 8.59 74.15 ± 9.2 | 134.015 ± 14.2 137.91 ± 16.99 | NA NA | NA NA | NA NA | Intervention group: 87.5% (21 out of 24) Control group: 88.5% (23 out of 26) | Data not available. | |||||||
Emam et al. − 2020 | Egypt | 60 (30 in intervention and 30in control) | Subjects (aged 12 years or older) with symptomatic acute ALP poisoning and a history of rice tablets ingestion presented within 6 h from exposure with no previous medical treatment for phosphide intoxication in any medical center prior to admission were included | Dose 1: 150 mg/kg IV, mixed in 200 mL of D5W and infused over 1 h. Dose 2: 50 mg/kg IV, mixed in 500 mL D5W and infused over 4 h. Dose 3: 100 mg/kg IV, mixed in 1000 mL. D5W and infused over 16 h. | 24.4 ± 10.5 24.4 ± 9.66 | M/F18.3%/31.6% M/F18.3%/31.6% | 92.16 ± 21.9 94.83 ± 21.1 | 104.57 ± 20.5 104.27 ± 20.5 | NA NA | NA NA | NA NA | Intervention group: 20% (6 out of 30) Control group: 43.3% (13 out of 30) | Intervention group: 23.3% (7 out of 30) Control group: 20% (6 out of 30) | |||||||
El-Ebiary et al. − 2017 | Egypt | 30 (15 in intervention and 15 in control) | Patients (male or female, aged 18 years or older) with symptomatic acute ALP poisoning (deliberate or accidental), were included | Patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/Kg IV infusion every 4 h up to 17 doses, In addition, the routine treatment was given, and it consists of patient resuscitation, gastric decontamination | From 18–28 years old : (86.7%) (80.0%) From 28–38 years old : (13.3%) (6.7%) From 38–48 years old: (0.0%) (13.3%) | M/F23.3%/26.6% M/F20%/30% | Hypotension (73.3%)(93.3%) Hypertension (6.7%)(0.0%) Normal (20.0%)(6.7%) | Undetected (0.0%) (13.3%) Bradycardia (0.0%) (6.7%) Tachycardia (33.3%) (46.7%) Normal (66.7%) (33.3%) | On admission 17.48 ± 7.48 16.23 ± 7.91 After treatment 2.79 ± 1.82 17.26 ± 6.39 - | On admission 1.99 ± 0.77 3.23 ± 2.16 After treatment 0.66 ± 0.26 2.15 ± 1.44 | NA NA | Intervention group: 33.3% (5 out of 15) Control group: 80% (12 out of 15) | Intervention group: 46.7% (7 out of 15) Control group: 80% (12 out of 15) | 48 (13–48) 12 (8–13) |